



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Technically  
Speaking

**CEDARLANE**<sup>®</sup>  
[www.cedarlanelabs.com](http://www.cedarlanelabs.com)



Conveniently Delivering You Today's Innovations  
for the Science of Tomorrow™

**Rabbit Anti-SARS-CoV-2 Spike RBD  
Polyclonal Antibody**

Catalogue#	Format	Size	Concentration
CL7891AP-S	Purified	20 µg	1.0 mg/ml
CL7891AP	Purified	200 µg	1.0 mg/ml
CL7891AP-BULK	Purified	1 mg	1.0 mg/ml
CL7891B	Biotin	100 µg	0.1 mg/ml
CL7891HP	HRPO	100 µg	1.0 mg/ml

Isotype: Rabbit IgG

**DESCRIPTION:**

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Like other coronaviruses, SARS-CoV-2 is comprised of four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. The spike (S) protein is a type I transmembrane glycoprotein that is comprised of two subunits, S1 and S2. Within the S1 subunit is a receptor binding domain (RBD), that is responsible for binding to the receptor angiotensin converting enzyme 2 (ACE2) and allowing the virus to enter host cells. As the RBD is responsible for initial viral entry into the host cell, it has become an attractive target for therapeutics and vaccines.

**PRESENTATION:**

**Purified:** Purified IgG buffered in PBS and 0.02% NaN<sub>3</sub>. (Purified from serum via Protein A Chromatography). For maximum recovery of contents, spin down tube before use.

**Biotin:** Biotin conjugated IgG buffered in PBS, 0.02% NaN<sub>3</sub> and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml.

**HRPO:** HRPO conjugated IgG buffered in PBS with 40% glycerol (v/v) and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml. No NaN<sub>3</sub> with other preservatives.

**STORAGE/STABILITY:**

For all formats, store at + 4°C. For long term storage, aliquot and freeze unused portion at -20°C in volumes appropriate for single usage. Avoid freeze/thaw cycles.

**SPECIFICATION:**

**Immunogen:** Recombinant 2019-nCoV Spike protein S1 subunit, receptor-binding domain (RBD) (aa319-541) expressed in CHO cells.

*Continued Overleaf...*

Visit our website for your local distributor.

**CEDARLANE**<sup>®</sup>

[www.cedarlanelabs.com](http://www.cedarlanelabs.com)

An ISO 9001:2015 and ISO 13485:2016  
registered company.

**In CANADA: Toll Free: 1-800-268-5058**

4410 Paletta Court, Burlington, ON L7L 5R2 ph: (289) 288-0001, fax: (289) 288-0020  
e-mail: [general@cedarlanelabs.com](mailto:general@cedarlanelabs.com)

**In the USA: Toll Free: 1-800-721-1644**

1210 Turrentine Street, Burlington, NC 27215 ph: (336) 513-5135, fax: (336) 513-5138  
e-mail: [service@cedarlanelabs.com](mailto:service@cedarlanelabs.com)

Specificity: 2019-nCoV Spike protein S1 subunit, receptor-binding domain (RBD) (aa319-541).

Applications: This antibody is suitable for use in ELISA (1:16K – 1:32K dilution). This antibody has not been tested in other applications.

**REFERENCES:**

1. Gorbalenya AE, et al. (2020). The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology*. 5 (4): 536–544.
2. Wu C, et al. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharmaceutica Sinica B*. 10 (5): 766–788.
3. Xiao X, et al. (2004) The SARS-CoV S glycoprotein. *Cell Mol Life Sci*. 61(19-20):2428-2430.
4. Lan J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*. 2020;581(7807):215-220.

**Optimum conditions for use of this antibody in analytical procedures should be established in each laboratory**

**For Research Use Only**

JK 11/03/20